Cargando…

Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation

INTRODUCTION: Feline leukemia virus (FeLV) is a chronic disease that leads to the weakening of a cat's immune system. Platelet-rich plasma (PRP) offers therapeutic effects for multiple diseases, the use of PRP and growth factors (GFs) determination could be an alternative treatment to improve t...

Descripción completa

Detalles Bibliográficos
Autores principales: Miguel-Pastor, Laura, Satué, Katy, Chicharro, Deborah, Peláez, Pau, Torres-Torrillas, Marta, Carrillo, José M., Cerón, José J., Sopena, Joaquín J., Rubio, Mónica
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909748/
https://www.ncbi.nlm.nih.gov/pubmed/36777664
http://dx.doi.org/10.3389/fvets.2023.1110055
_version_ 1784884640586137600
author Miguel-Pastor, Laura
Satué, Katy
Chicharro, Deborah
Peláez, Pau
Torres-Torrillas, Marta
Carrillo, José M.
Cerón, José J.
Sopena, Joaquín J.
Rubio, Mónica
author_facet Miguel-Pastor, Laura
Satué, Katy
Chicharro, Deborah
Peláez, Pau
Torres-Torrillas, Marta
Carrillo, José M.
Cerón, José J.
Sopena, Joaquín J.
Rubio, Mónica
author_sort Miguel-Pastor, Laura
collection PubMed
description INTRODUCTION: Feline leukemia virus (FeLV) is a chronic disease that leads to the weakening of a cat's immune system. Platelet-rich plasma (PRP) offers therapeutic effects for multiple diseases, the use of PRP and growth factors (GFs) determination could be an alternative treatment to improve the quality of life in these patients. The objectives of this study were to determine and compare the concentration of platelets (PLTs), red blood cells (RBCs) and white blood cells (WBCs) between samples of whole blood (WB), PRP and platelet-poor plasma (PPP) fractions, and to evaluate the concentration of platelet-derived growth factor BB (PDGF-BB) and transforming growth factor β1 (TGF-β1) in both fractions in FeLV cats using a PRGF(®)-Endoret(®) protocol previously standardized in this species. METHODS: WB was collected from 11 asymptomatic FeLV-positive cats. PRP and PPP was obtained following PRGF(®)-Endoret(®) technology according to centrifugation at 265 g for 10 min. Cellular components, RBCs, WBCs, PLTs, and the PDGF-BB and TGF-β1 concentrations in PRP and PPP fractions were determined. RESULTS: PLT in the PRP fraction was statistically higher than WB and PPP fraction, with no statistical differences between WB and PPP. PLT concentration increased 1.4 times in PRP fraction compared to WB. Mean platelet volume (MPV) did not differ significantly between the WB, PRP, and PPP fractions. Compared to WB, the absolute numbers of RBCs and WBCs were decreased by 99% and more than 95% in the PRP and PPP fractions, respectively. TGF-ß1 concentrations increased in PRP vs. PPP, with no changes in PDGF-BB. DISCUSSION: Based on the degree of PLT enrichment and the absence of RBCs and WBCs, this blood product could be classified as a Pure Platelet-Rich Plasma (P-PRP). The presence of GFs in PRP and PPP samples suggests that the PRGF(®)-Endoret(®) methodology is suitable for obtaining PRP in FeLV cats, despite future studies are necessary to optimize the technique, standardize the results and assess clinical efficacy.
format Online
Article
Text
id pubmed-9909748
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-99097482023-02-10 Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation Miguel-Pastor, Laura Satué, Katy Chicharro, Deborah Peláez, Pau Torres-Torrillas, Marta Carrillo, José M. Cerón, José J. Sopena, Joaquín J. Rubio, Mónica Front Vet Sci Veterinary Science INTRODUCTION: Feline leukemia virus (FeLV) is a chronic disease that leads to the weakening of a cat's immune system. Platelet-rich plasma (PRP) offers therapeutic effects for multiple diseases, the use of PRP and growth factors (GFs) determination could be an alternative treatment to improve the quality of life in these patients. The objectives of this study were to determine and compare the concentration of platelets (PLTs), red blood cells (RBCs) and white blood cells (WBCs) between samples of whole blood (WB), PRP and platelet-poor plasma (PPP) fractions, and to evaluate the concentration of platelet-derived growth factor BB (PDGF-BB) and transforming growth factor β1 (TGF-β1) in both fractions in FeLV cats using a PRGF(®)-Endoret(®) protocol previously standardized in this species. METHODS: WB was collected from 11 asymptomatic FeLV-positive cats. PRP and PPP was obtained following PRGF(®)-Endoret(®) technology according to centrifugation at 265 g for 10 min. Cellular components, RBCs, WBCs, PLTs, and the PDGF-BB and TGF-β1 concentrations in PRP and PPP fractions were determined. RESULTS: PLT in the PRP fraction was statistically higher than WB and PPP fraction, with no statistical differences between WB and PPP. PLT concentration increased 1.4 times in PRP fraction compared to WB. Mean platelet volume (MPV) did not differ significantly between the WB, PRP, and PPP fractions. Compared to WB, the absolute numbers of RBCs and WBCs were decreased by 99% and more than 95% in the PRP and PPP fractions, respectively. TGF-ß1 concentrations increased in PRP vs. PPP, with no changes in PDGF-BB. DISCUSSION: Based on the degree of PLT enrichment and the absence of RBCs and WBCs, this blood product could be classified as a Pure Platelet-Rich Plasma (P-PRP). The presence of GFs in PRP and PPP samples suggests that the PRGF(®)-Endoret(®) methodology is suitable for obtaining PRP in FeLV cats, despite future studies are necessary to optimize the technique, standardize the results and assess clinical efficacy. Frontiers Media S.A. 2023-01-26 /pmc/articles/PMC9909748/ /pubmed/36777664 http://dx.doi.org/10.3389/fvets.2023.1110055 Text en Copyright © 2023 Miguel-Pastor, Satué, Chicharro, Peláez, Torres-Torrillas, Carrillo, Cerón, Sopena and Rubio. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Veterinary Science
Miguel-Pastor, Laura
Satué, Katy
Chicharro, Deborah
Peláez, Pau
Torres-Torrillas, Marta
Carrillo, José M.
Cerón, José J.
Sopena, Joaquín J.
Rubio, Mónica
Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation
title Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation
title_full Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation
title_fullStr Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation
title_full_unstemmed Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation
title_short Evaluation of Platelet-Rich Plasma by means of PRGF(®)-Endoret(®) protocol in leukemia cats: PDGF-BB and TGF-ß1 valuation
title_sort evaluation of platelet-rich plasma by means of prgf(®)-endoret(®) protocol in leukemia cats: pdgf-bb and tgf-ß1 valuation
topic Veterinary Science
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9909748/
https://www.ncbi.nlm.nih.gov/pubmed/36777664
http://dx.doi.org/10.3389/fvets.2023.1110055
work_keys_str_mv AT miguelpastorlaura evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT satuekaty evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT chicharrodeborah evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT pelaezpau evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT torrestorrillasmarta evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT carrillojosem evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT ceronjosej evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT sopenajoaquinj evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation
AT rubiomonica evaluationofplateletrichplasmabymeansofprgfendoretprotocolinleukemiacatspdgfbbandtgfß1valuation